BPC-157 vs Pentadeca Arginate
The same fifteen-amino-acid healing pitch twice: one molecule with a deep rodent literature behind it, and one with a near-empty file of its own.
Short answer
BPC-157 and pentadeca arginate are both graded preclinical / minimal, which leaves little or no controlled human data to choose between them. BPC-157 is the one sold for healing, recovery and gut health, while pentadeca arginate targets healing and recovery. Both are sold gray-market as research chemicals.
BPC-157
Almost entirely animal data; no validated human dose and no controlled efficacy trials.
Full BPC-157 evidence reviewPentadeca Arginate
PDA
Marketed as a more stable upgrade on BPC-157, but it has almost no research of its own — the evidence base is borrowed and preclinical.
Full Pentadeca Arginate evidence reviewBPC-157 vs Pentadeca Arginate: head to head
- FDA status / approved use
BPC-157
Not an approved drug anywhere; typically sold labeled for research use onlyPentadeca Arginate
Not an approved drug anywhere; sold online as research use only- Marketed for
BPC-157
Healing, recovery, gut healthPentadeca Arginate
Healing, recovery (a 'stable BPC-157')- Outcome areas
BPC-157
Injury recovery / tissue repair; Gut healthPentadeca Arginate
Injury recovery / tissue repair- Evidence grade
BPC-157
Preclinical / minimalPentadeca Arginate
Preclinical / minimal- How it works
BPC-157
Appears to act on multiple repair pathways, including nitric-oxide and vascular systemsPentadeca Arginate
Arginate-salt form of a BPC 157-like peptide; benefits extrapolated from BPC 157- Route and dosing
BPC-157
Injection; no established human dosePentadeca Arginate
Injected; no established dose- Headline human result
BPC-157
Not establishedPentadeca Arginate
Not established- Strongest evidence
BPC-157
Pharmaceutics review, 2026. Little or no controlled human outcome data for the marketed useBPC-157 evidence reviewPubMed 42198317Pentadeca Arginate
Sikiric, Inflammopharmacology 2024. Little or no controlled human outcome data for the marketed usePentadeca Arginate evidence reviewPubMed 38980576- Key safety signal
BPC-157
No human safety profile; research-grade products carry contamination, mis-dosing and mislabeling risksPentadeca Arginate
Unknown purity, sterility and dosing; no direct human or animal studies- How it is obtained
BPC-157
Sold gray-market as a research chemical; no approved or legitimately compounded human productPentadeca Arginate
Sold gray-market as a research chemical; no approved or legitimately compounded human product
| BPC-157 | Pentadeca Arginate | |
|---|---|---|
| FDA status / approved use | Not an approved drug anywhere; typically sold labeled for research use only | Not an approved drug anywhere; sold online as research use only |
| Marketed for | Healing, recovery, gut health | Healing, recovery (a 'stable BPC-157') |
| Outcome areas | Injury recovery / tissue repair; Gut health | Injury recovery / tissue repair |
| Evidence grade | Preclinical / minimal | Preclinical / minimal |
| How it works | Appears to act on multiple repair pathways, including nitric-oxide and vascular systems | Arginate-salt form of a BPC 157-like peptide; benefits extrapolated from BPC 157 |
| Route and dosing | Injection; no established human dose | Injected; no established dose |
| Headline human result | Not established | Not established |
| Strongest evidence | Pharmaceutics review, 2026. Little or no controlled human outcome data for the marketed useBPC-157 evidence reviewPubMed 42198317 | Sikiric, Inflammopharmacology 2024. Little or no controlled human outcome data for the marketed usePentadeca Arginate evidence reviewPubMed 38980576 |
| Key safety signal | No human safety profile; research-grade products carry contamination, mis-dosing and mislabeling risks | Unknown purity, sterility and dosing; no direct human or animal studies |
| How it is obtained | Sold gray-market as a research chemical; no approved or legitimately compounded human product | Sold gray-market as a research chemical; no approved or legitimately compounded human product |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Preclinical / minimal:
- Evidence is largely animal, in-vitro, or anecdotal. Little or no controlled human outcome data for the marketed use.
Our verdict
BPC-157 at least owns its evidence: a consistent preclinical resume across tendon, ligament, muscle, bone and gastrointestinal models, though there are no published randomized human trials for any indication, no established dosing and no human pharmacokinetics. Pentadeca arginate is marketed as a more stable, more soluble arginate-salt upgrade, but there is essentially no independent published research on PDA specifically; nearly every benefit claimed for it is borrowed from the BPC-157 literature on the untested assumption that the salt form behaves identically. Both are unapproved and sold research-use-only, so this is a choice between a thin preclinical base and a borrowed one, not between two treatments.
BPC-157 fits if
Someone who wants to read the actual literature behind this class, since BPC-157 is the molecule the studies were run on.
Pentadeca Arginate fits if
Hard to name one on evidence grounds; PDA's only distinct claim is formulation stability, which says nothing about whether it does anything in a person.
BPC-157 vs Pentadeca Arginate: common questions
- Is either BPC-157 or pentadeca arginate FDA-approved?
- No. BPC-157 is not an approved drug anywhere; typically sold labeled for research use only. Pentadeca arginate is not an approved drug anywhere; sold online as research use only.
- Which has stronger human evidence, BPC-157 or pentadeca arginate?
- Neither. Both are graded preclinical / minimal, with little or no controlled human outcome data for the marketed use. The key source for BPC-157 is Pharmaceutics review, 2026; for pentadeca arginate, it is Sikiric, Inflammopharmacology 2024.
- What are the main safety concerns with BPC-157 and pentadeca arginate?
- BPC-157 has no human safety profile; research-grade products carry contamination, mis-dosing and mislabeling risks. For pentadeca arginate, watch for unknown purity, sterility and dosing; no direct human or animal studies.
Key studies behind each
BPC-157
- Sikiric P, Sever M, Krezic I, et al. (2024). New studies with stable gastric pentadecapeptide protecting gastrointestinal tract: significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection. Inflammopharmacology. PubMed 38980576
- Gwyer D, Wragg NM, Wilson SL. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. PubMed 30915550
- McGuire FP, Martinez R, Lenz A, et al. (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. PubMed 40789979
- Bilic Z, Gojkovic S, Kalogjera L, et al. (2021). Novel insight into Robert's cytoprotection: complex therapeutic effect of cytoprotective pentadecapeptide BPC 157 in rats with perforated stomach through modulation of the nitric-oxide system. J Physiol Pharmacol. PubMed 35485358
Pentadeca Arginate
- Sikiric P, Sever M, Krezic I, et al. (2024). New studies with stable gastric pentadecapeptide protecting gastrointestinal tract: significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection. Inflammopharmacology. PubMed 38980576
- Gwyer D, Wragg NM, Wilson SL. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. PubMed 30915550
- McGuire FP, Martinez R, Lenz A, et al. (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. PubMed 40789979
- Bilic Z, Gojkovic S, Kalogjera L, et al. (2021). Novel insight into Robert's cytoprotection: complex therapeutic effect of cytoprotective pentadecapeptide BPC 157 in rats with perforated stomach through modulation of the nitric-oxide system. J Physiol Pharmacol. PubMed 35485358
The full evidence reviews
- BPC 157: what the evidence actually shows (and what it doesn't)
The 'healing peptide' has a deep rodent literature and almost no human data. A straight read of where the science stands.
Updated October 2026
- Pentadeca Arginate (PDA): the evidence behind the BPC 157 successor
PDA is marketed as a more stable upgrade on BPC 157 — but it has almost no research of its own. A straight read of a borrowed evidence base.
Updated August 2026
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm BPC-157 availability before ordering.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.
- Oak LongevityPartner
Low-cost sermorelin within a broader longevity stack
- HealthRXPartner
Compounded sermorelin within a broad longevity and weight-care menu
Bodybuilding Health+PartnerSermorelin from Bodybuilding.com's telehealth program
Provider reviews we publish: Always Wellness and RecoveryAmbiante Health & WellnessBlis MDCalifornia Trim ClinicClinic SecretDr. Gillis' Wellness Center